Bone Metastatic Non-small Cell Lung Cancer
Conditions
Brief summary
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of c-met, tumor angiogenesis and tumor cell migration.
Interventions
DRUGAL2846
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1.Understood and signed an informed consent form. 2.18 years and older; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months. 3.Histologically confirmed advanced non-small cell lung cancer with at least one bone metastatic lesion with bone destruction. 4.Has received at least two systematic treatment regimens that failed or were unable to tolerate treatment. 5.EGFR, ALK gene mutations are negative. 6.Adequate laboratory indicators. 7.No pregnant or breastfeeding women, and a negative pregnancy test.
Exclusion criteria
* 1.Small cell lung cancer. 2. Diagnosed and/or treated additional malignancy within 5 years with the exception of cured cervical carcinoma in situ and non-melanoma skin cancer. 3\. Has received radiotherapy, chemotherapy and surgery before and less than 4 weeks from the first administration and less than 5 half-lives of oral targeted drugs after the completion of treatment. 4\. Has received systemic radionuclide therapy or semi-extracorporeal radiation for bone metastases. 5\. Has known to be allergic to the study drug or any of its excipients. 6. Has symptomatic brain metastases, spinal cord compression, and cancerous meningitis within 8 weeks,or brain or pia mater disease confirmed by CT or MRI examination before the first dose. 7\. Has adverse events caused by previous therapy that did not recover to ≤ grade 1, with the exception of alopecia or ≥ grade 2 neurotoxicity caused by Oxaliplatin. 8\. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear. 9\. Has spinal cord compression or mandibular osteonecrosis. 10.Has multiple factors that affect oral medications. 11.Has gastroduodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases or other conditions judged by the investigator that may cause gastrointestinal bleeding or perforation. 12.Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. 13\. Has severe acute comorbidities before the first dose. 14. Has participated in other clinical trials within 4 weeks before the first dose. 15.According to the investigators' judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The time when the first bone-related event (SRE) occurred | up to 96 weeks | The time from the randomization to the first occurrence of any meeting of bone-related event criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | up to 96 weeks | PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator. |
| Overall response rate (ORR) | up to 96 weeks | Percentage of participants achieving complete response (CR) and partial response (PR). |
| Duration of Response (DOR) | up to 96 weeks | The time when the participants first achieved complete or partial remission to disease progression. |
| Overall survival (OS) | up to 96 weeks | OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. |
| Effectiveness of improving average daily pain intensity on week 8 and 16 (Refer to Brief pain inventory (BPI) and the Verbal rating scale (VRS) | on 8 and 16 week | Referring to Brief pain inventory (BPI) and Verbal rating scale (VRS), the percentage of improvement in the average intensity of pain confirmed at week 8 and week 16 compared to the previous average intensity. |
| Biomarkers | up to 96 weeks | Relationship between drug efficacy and related biomarkers such as C-Met, FGFR, c-Kit, RET. |
| Disease control rate（DCR） | up to 96 weeks | Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD). |
Countries
China
Contacts
Primary ContactHongming Pan, Doctor
Outcome results
None listed